New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
11:34 EDTPTNNoble Financial says regulatory developments positive for Palatin Tech
Noble said Sprout Pharmaceuticals received FDA clarity for the re-submission of the flibanserine NDA for female sexual dysfunction, or FSD, which provides efficacy endpoints. The analyst said Palatin can now plan Phase III trials for FSD with "agreed upon" endpoints, and when combined with regulatory clarity, should increase interest from big Pharma. Shares are Buy rated with a $2.50 price target.
News For PTN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
16:13 EDTPTNPalatin Tech files to sell 18.63M shares of common stock for holders
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use